To obtain documents, log on:
:
Not registered? Register me now
 

Public Higher Education Bulletin

 
University of Illinois at Chicago
Exemption #JJW973

Announcement of an Exempt Purchase

Award Info Published Friday June 26, 2020
Awarded to:
Vendor: Cardinal Health, Dublin, OH
Amount: An estimated $1,250,000
Terms:
An estimated start date of 7/1/2020 through 6/30/2025
Renewals:
None
The University award process may be delayed up to thirty days as this award goes through a state approval process.
First published Friday, June 26, 2020
The University awarded a contract for Ra 223 (Xofigo).
The drug radium Ra 223 (Xofigo) is for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastases. Algeta is the sole manufacture of Ra 223 (Xofigo) and Cardinal is the sole distributor in the United States.
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical services necessary for the delivery of care and treatment at medical, dental, or veterinary teaching facilities utilized by SIU or U of I (30 ILCS 500 / 1-13(b-5)) This drug is needed to treat cancer patients. Currently Ra 223 is the only isotope available for treatment of patients with castration-resistant prostate cancer.

For instructions on how to obtain a comprehensive purchase description, disclosure or contract forms, contact:
Jeffrey Walsh
University of Illinois at Chicago
Purchasing Division (M/C 560)
809 South Marshfield Avenue
Chicago, IL 60612-7203
Phone: (312) 355-3568
FAX: (312) 996-3135

The State of Illinois has a policy to encourage prospective vendors to hire qualified veterans, minorities, females, persons with disabilities and ex-offenders.

Bulletin Navigation

 
To obtain documents, log on:
Exemption Document
  • JJW973-CardinalHealth.pdf (2 MB)